GlaxoSmithKline plc announced a five-year collaboration with the University of California to establish a state-of-the-art laboratory for CRISPR technologies, the Laboratory for Genomics Research (LGR). The new laboratory will explore how gene mutations cause disease and develop new technologies using CRISPR to rapidly accelerate the discovery of new medicines. With the recent explosion of information…
GlaxoSmithKline to Acquire Tesaro, Gaining PARP Inhibitor Zejula
GlaxoSmithKline and Tesaro have entered into a definitive agreement pursuant to which GSK will acquire Tesaro, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion. The proposed transaction will significantly strengthen GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology. Tesaro is a commercial-stage biopharmaceutical…
GSK Receives Breakthrough Therapy Designation For Meningitis Vaccine
GSK’s meningitis B vaccine Bexsero receives Breakthrough Therapy Designation from U.S. FDA for prevention of invasive meningococcal disease in children 2-10 years of age. Bexsero is the first vaccine in the world to receive the Breakthrough Therapy Designation (BTD) twice. In 2014, Bexsero received BTD for development in the prevention of invasive meningococcal disease (IMD)…
GSK Flu Vaccine Now Approved In U.S. For Infants 6-Months And Up
GSK receives FDA approval for expanded indication for Fluarix Quadrivalent (influenza vaccine) for persons 6 months and older. GSK has received approval from the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research expanding the indication for Fluarix Quadrivalent (influenza vaccine) to include use in persons 6 months and older. Prior to this,…
